Loading...
HomeMy WebLinkAboutPackets - Council Packets (1083) AGENDA ORO VALLEY TOWN COUNCIL STUDY SESSION FEBRUARY 23, 2005 ORO VALLEY COUNCIL CHAMBERS 11000 N. LA CANADA DRIVE STUDY SESSION AT OR AFTER 4:30 PM CALL TO ORDER ROLL CALL 1. PRESENTATION BY DR. RAY WOOLSEY REGARDING THE CRITICAL PATH TO ACCELERATE THERAPIES INSTITUTE (C-PATH) 2. PRESENTATION BY BRUCE WRIGHT, VICE PRESIDENT FOR ECONOMIC DEVELOPMENT, UNIVERSITY OF ARIZONA — GLOBAL ADVANTAGE 3. DISCUSSION REGARDING TOWN COUNCIL STUDY SESSIONS START TIME ADJOURNMENT POSTED: 02/16/05 4:30 p.m. Ih When possible, a packet of agenda materials as listed above is available for public inspection at least 24 hours prior to the Council meeting in the office of the Town Clerk between the hours of 8:00 a.m. — 5:00p.m. The Town of Oro Valley complies with the Americans with Disabilities Act (ADA). If any person with a disability needs any type of accommodation, please notify the Town Clerk's Office at 229-4700. 1 TOWN OF ORO VALLEY STUDY SESSION COUNCIL COMMUNICATION MEETING DATE: FEBRUARY 23, 2005 TO: HONORABLE MAYOR & COUNCIL MEMBERS FROM: JEFFREY H. WEIR, CEcD ECONOMIC DEVELOPMENT ADMINISTRATOR SUBJECT: PRESENTATION BY DR. RAY WOOSLEY CONCERNING THE CRITICAL PATH TO ACCELERATE THERAPIES INSTITUTE (C-PATh). SUMMARY: Dr. Raymond L. Woosley, MD, PhD, President of the C-PATh Institute, will make a presentation to the Mayor and Council about the mission and facilities plan for this new and important drug therapy acceleration proposal. The mission of the C-PATh Institute is p to foster and conduct research and educational programs that will enable the Federal Food and Drug Administration (FDA) and the pharmaceutical industry to accelerate the development of safe innovative new medicines. At the conclusion of the presentation Dr. Woosley will ask the Council for future consideration of a financial commitment of $ 25,000 per year for five years (the like amount of commitment made by the Town of Marana). Dr. Woosley is prepared to respond to the Council's inquiries concerning potential facility locations within Oro Valley. ATTACHMENTS: 1. A three page executive summary about the C-PATh Institute. 2. A copy of the PowerPoint presentation that will be made by Dr. Woosley. r \______ „Z- , i ii. /, _ c IC!,';z - i L,k 0 AL; a ‘J i { JEFFREY H. WEIR, CEcD ECONOMIC DEVELOPMENT ADM. , , /ir e f 4i CHUCK SWEET TOWN MANAGER Attachment One C-PATh INSTITUTE EXECUTIVE SUMMARY 2/2/05 The C-Path Institute The Critical Path to Accelerate Therapies Institute the C-Path Institute is to foster and conduct research and educational programs The mission of pharmaceutical will enable thethe and FDA industry to accelerate the development of safe innovative new medicines. It is a free-standing non-profit organization formed to facilitate collaboration among the Universityof Arizona (UA), SRI International (SRI) and the U.S. Food and Drug Administration (FDA). Background In the last decade U.S.Spharmaceutical research and development expenditures have risen 250% and in the past five years the National Institutes of Health (NIH) budget for biomedical Although this has led to many advances in basic biomedical science, the research has doubled g p number of new medical therapies submitted for FDA approval over this period has declined. There is growing recognitionmajor that a ma"or factor contributing to the bottleneck in drug development is the time-consumingand inefficient process for preclinical and clinical development. The science of drugdevelopment has not evolved to match the advances that are occurring in the basic sciences. As noted below, there has been little effort invested to improve thep rocess of drug development that begins after drug discovery. The Pharmaceutical Research and Manufacturers of America, PhRMA, estimate that the industry spend s end $0.8 - 1.7 billion and 12-15 years of research and development on average to bring a product to market. This leaves only 2-5 years of patent life and market exclusivity beforegenericcompetition determines the price of drugs. With such a limited time to recoup their investment, industryis forced to charge increasingly higher prices. The rapidly escalating prices for branded prescription medications are resulting in the consideration of national drug p policies and price controls that would seriously threaten the future of the research-based pharmaceutical industry i al in the United States. Higher development costs also limit accessibility of medications and discourage development of medications for orphan diseases, or diseases that affect primarily low income populations. The "Critical Path" FDA has concluded an analysis of the causes for the delays in drug development. In The y March of 2004, the Food and Drug Administration released a white paper entitled "Innovation or Stagnation?" This report, often termed the "critical path initiative," included a challenge: g p "We must modernize the critical development path that leads from scientific discovery to the pa tient." The FDA calls for research to develop and validate new tools and methods for testing new medicines. The FDA is confident that this research and the resulting new tools can enable more rapid and informative drugdevelopment such as occurred for AIDS drugs in the 1980s and 90s. In response to the AIDS crisis, the FDA worked closely with the pharmaceutical industry to developnew and innovative methods for the rapid development of new drugs for AIDS and HIV. This resulted in development times as short as two-three years for these drugs the same time period, the average development time for all drugs slowed to >12 while, during years. This experience clearly demonstrates that it is feasible to accelerate drug development without taking unnecessary and dangerous shortcuts. The pharmaceutical industry also has an acute need for employees with advanced training in Typical academic programs today do not adequately prepare scientists in drug development. p g applicable fields expertiseregulatory of such as toxicology, regulations for Good Laboratory Practices (GLP) and Good ManufacturingPractice (GMP), clinical product GMP, clinical pharmacology and Good Clinical Practice (GCP)trial management. The C-Path Institute r of a $400 000grant from the Arizona Commerce and Economic Development With the award Fund, planning begun has be un for The C-Path Institute (The Critical Path to Accelerate Therapies Institute). The mission sion of C-Path will be to conduct the educational and research programs that pharmaceutical enable the and d the industry to accelerate the development of safe innovative pharmaceuticals.rmaceuticals. The Institute is a non-profit corporation affiliated with three founding parteUniversity partners: the of Arizona (UA), SRI International (formerly Stanford Research Institute); and the Food and Drug Administration (FDA). Each will contribute to the Institute. The University of Arizona will serve as home for the unique strengths . ' educational and research programs and provide an environment of innovation and Institute's p g inquiry. Theparticipating FDA scientists will provide the first hand knowledge of the 1 process and a wealth of experience in the evaluation of new pharmaceutical agents. regulatory SRIbring will practical experience in modern pharmaceutical development, scientific expertise and a track record of commercializing innovations. ion: The Institute will have an Operating Board and a National Community Board Organization: with membersjointly chosen bythe President of the UA, the President of SRI and the Commissioner ioner of the FDA (or their designates). The National Community Board will include representatives of the City of Tucson, Pima County, the three founding partners and the community.. The C-PATh will also have a scientific advisory board of experts in drug development representing the University of Arizona, SRI, FDA and leading international p g institutions. programs: These programs will be designed to provide the most advanced and Educationalp g p g innovative educational experiences for those seeking careers in the pharmaceutical industry or already workingin the industryand wishing to advance their skills. It is anticipated that those a y programs will be available at the UA to study global drug development issues. It will also provide a curriculum for the global pharmaceutical community that includes FDA regulatory education, trainingand policystudy. Real world experiences through internships with SRI and otherpharmaceutical partners will be an integral part of the education. The current degree (PhD, PharmD, MS, MBA) and certificate programs of the University will be expanded to meet the educational needs of students and the industry as the programs grow. An interdisciplinaryro MS and PhD degrees in Drug Development Science is program ram awarding being planned at this time. Research Programs: The University of Arizona will seek to expand its already outstanding faculty to increase its capabilities to develop innovative methods for accelerated drug a y p . discovery and development. This will build upon the research already in place at the UA that d ry p 2 includes a research contract from the FDA Office of Women's Health for the testing of drugs during pregnancy. Also, the University of Arizona is one of seven sites with federally funded Centers for Education and Research on Therapeutics. This Center already works closely with the FDA conducting educational and research programs designed to reduce adverse events from drug interactions. SRI is also a major recipient of NIH funds for preclinical development of drugs and vaccines. The results of the research conducted in the Institute and in other institutions will be rapidly incorporated into the curriculum of the Institute. C-Path will not directly develop new drugs. However, it will expedite drug development through its programs that bring together experts in drug discovery and development from academia, industry and the FDA. The goal is to accelerate the development of safer medicines, particularly for orphan illnesses and critical diseases such as cancer where innovation and progress will have the greatest impact. Timelines and Financial Plan: The University of Arizona, SRI and the FDA have entered into a 4 month planning phase in which a work plan and a financial plan will be created. During this phase, each partner is identifying members of their current staff who have the scientific expertise required to execute the work plan and who are willing to participate in the C-Path programs. These scientists will be the initial participants in the C-Path. Once the work plan is completed, operating budgets for the first five years will be constructed. It is now estimated that a minimum of$1.5 million per year in operating capital will be needed to hire the required staff and to support the initial activities of the C-Path. Almost $9 million in commitments for donations from the Southern Arizona community have been obtained to underwrite the first five years of startup costs for the C-Path. C-Path is a 501 c3 non-profit organization with the mission of conducting research and education programs to accelerate the development of safe innovative drugs. In February of 2005, the work plan and a financial plan will be presented to the founding partners and the community members who have committed the startup funds. It is expected that the C-Path will become fully operational within months. The Institute is expected to become self sustaining within the first 5 years and operate on funding from government agencies, unrestricted endowment from pharmaceutical foundations, grants and donors. With continued success of C-Path, it is expected that the State of Arizona will be asked to construct a new facility for the C-Path and an adjoining research facility for SRI in a proposed Biotech park near the University of Arizona campus. Please direct any questions to: Raymond L. Woosley, MD, PhD President, The C-Path Initiative 520-626-7384 RWoosley@C-Path.org 3 Attachment Two C-PATh INSTITUTE POWERPOINT PRESENTATION Innovations in Pharmaceutical Development An opportunity in Arizona The rising cost and safety of medications are two of the greatest concerns across the nation. An opportunity in Arizona New Pharmaceuticals It's not just the ideas. . €32 1 BIOSCIENCES 1 „,„. FDA It's the translatiQj)! AppRoyAL Clinical;Trials Toxicology tillt, .-..., Pharmacokinetics ADME Manufacturing (4 Formulation i, .: , .......i MMedicinal ' Chemistry ..,...., ,t-'-- Res :Ir,• Y t a ' ' . s"i BIOSCIENCES .I1l70I-7//b/7 S\.6:C .6\-Ori Challenge and Opportunity on the Critical Path to New Medical Products 10 year Trend in Biomedical R&D Spending -a-US Plio oceutical R&D Spending -a,Tot,NIH Budget 2.H • • zoa 1 US Pharmaceutical R&D . t 3• ,50-1 j \/ Total NIH Budget y100 j -----r 50 1 i 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 200.9 Year 2 10 year Trend in Major New Applications to FDA 70- • -a-Total NLAEs Reed by FDA .. -O-original Buts 60 o - 11 New Drug Applications a • 3 30 20— 111 New Biological Applications 10 1 1 1 1 1 r r II 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Year R&D Spending Increased, but Product Approvals Have Not... 35 R&D Spending 50 30 0 13 mei Approvals _ R&D Spending —25 O. C. 20 U1 CL 30 Q Po in 20 Q � 1361°1 10 f 5 O 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Sources Washington Analysis,LLC and PhRMA for 1990-2000,PhRMA website for 2001-2 May 16.2000 Investment Increased Per Successful Product 2.0 _ Investment required for one successful $1.7 Billion drug launch(discovery through launch) Launch 1.5— Phase III/File $1.1 Billion —777- Critical 1.0 *` r"r Path T Phase Ill/File Critical P.thl = a Phase'I Preclinical 0.5— Preclinical Discovery Discovery 0.0 1995-2000 2000-2002 SOURCL:Wiro0hover's In Vim:the Business&Medicine Heport. Barr drug economics model.200'3 Largest Delays are in Development Phases Figure 4:The Critical Path for Medical Product Development ti.,,,,, P`QMYix_ Pt o,linieal Agro+;al F, �c.:.ign cr clinical oevelvpmea Research Development l.:SUfiK:i1 ri,cov.,y Preparation 1 f 1 r 1 t,•1arkvt A�rlic:fic•.n \ I ,.________—.1 Discovery ` Critical Path I Critical Path to Market Why is the FDA calling for innovation? • Average drug approved by FDA takes 12-15 yrs & $1.7 Billion to get to market Th(‘ rrrml ninri`'-5 years of patent lif- Voli ( Hu !it it', • Few bio & pharma companies can afford that much time or that many dollars Is it possible to speed drug development without taking dangerous shortcuts? Yes !!!! HIV drugs were developed and approved in —3 years 4 "The goal of critical path research is to develop new...scientific and technical tools ...that make the development process more efficient and effective" Figure 5:Research Support for Product Development Prototype FDA Filingi Basic Design or f'rec�ir>ical Clinical Development t Launch prooai Rt earth !7i&Govery Deveioprnent) Preparation/ Translational Research Critical Path Research FDA Critical Pathways calls for • Innovation in drug development, AND • FDA/industry/academia partnerships 'Goal: Develop all drugs in <_ 3 years with greater evidence of effectiveness &safety 1 A proven concept 70t, National Center for Food Safety ; - t and Technology assuring the safety of : tf,::nation's fQoa supply... Moffett Center,U.Illinois,Chicago ifillr The NCFST is a unique research consortium composed of scientists from academia,the FDA and food-related industries. The Center provides a neutral ground where industry,academia and the FDA scientists address food safety issues. 10 _ .. , - 5 The C-PATH Institute The Critical Path to Accelerate Therapies • Academic home for Innovations in Drug Development • Learning Lab for students • Affiliation with FDA: highest possible quality and standards C-Path's Founding Partners /41111111111 \ International ��I//U CDA U,S,food and DiiigAdiiiinistnitioii /4 immmimmmimmmmimmi The `Chaperone'- Who we are SRI is ,iiry iipu:tu��;t i u vr'ycxr��.a iu1I •Founded by Stanford University in 1946 -A nonprofit corporation -Independent m 1970:changed name from Stanford Research Institute to SRI International in 1977 SRI headquarters, Menlo Park,CA •Acquired Sarnoff Corporation in 1987 (formerly RCA Laboratories) " •Combined power of 2,000 staff members Imo" - -800 with advanced degrees -More than 15 offices worldwide •Consolidated annual revenues of$300 million Sarnoff Corporation, SRI—State SRI— Princeton,NJ College,PA Washin ton D.C. r*. S 6 SRI Invented The Mouse, Windows And Hypertext ,..„ United States Patent Office P;fsasEnig,,,,,ro. • .7.:,"',,XI.:',..tg•-..".,t'„or-. ""J—t.Lcra,119 — • —3"' --„F:1,1=mgro,=4,ti=exilEic,:int.iS1140,, ------THE......a VS,1/4 SRI Initiated Both The First Wired And Wireless Internet Transmissions writ COI liporomot T kE A IVA Ntrwort.g. DEC In, 'IN... (r.4 SRI's spin-offs create value Pyramid Vision fie * . DIVA Technologies • . Secure Products Discer„ • (.'2ati'rlai:vuirsi AlterEgo Networks l-ightwaye Polyfuel 411,- ,IlnilliP ( C W.v...P- -...70,,gr.r. intuitive surgical Orc h id e-V ue AsteZ irVir 1.) * •NxtWave Communicabons LiteClips mict,c,:itioms Delays Zi:LLa)ceutical 7 C-Path Focus and Initial Vision Non-profit Institute with multiple Centers and collaborations that serve as a "neutral ground" for the FDA, academia and the pharmaceutical industry to work together for the public good. C-Path Mission Statement C-Path will create innovative programs in education and research that enable the safe acceleration of the process for developing new medicines. C-Path Programs FASTER SMARTER SAFER 8 C-Path Programs FAST CPED Faster Access to Critical Path Safer Therapeutics Admin. Educational ProgramsCore �, Programs 1--- PSAT Programs for Safe Accelerated Therapies C-Path "Products" C &FDA Public Databases Guidances* Web Tool ( Sery dated Methods ,Q Conferences 'V e07 ' l, off. C,- Education _ x=_.w,_. ,. _. _ , *Supporting FDA Guidance development efforts C-Path: Faster, Smarter, Safer t Thank You! 9 2 TOWN OF ORO VALLEY STUDY SESSION COUNCIL COMMUNICATION MEETING DATE: FEBRUARY 23, 2005 TO: HONORABLE MAYOR & COUNCIL MEMBERS FROM: JEFFREY H. WEIR, CEcD ECONOMIC DEVELOPMENT ADMINISTRATOR SUBJECT: PRESENTATION BY BRUCE WRIGHT, VICE PRESIDENT FOR ECONOMIC DEVELOPMENT, UNIVERSITY OF ARIZONA — GLOBAL ADVANTAGE. SUMMARY: Mr. Bruce Wright, Vice President for Economic Development, University of Arizona will make a presentation to the Mayor and Council about the vision and mission of the Global Advantage International Business Development Networking program. The vision of Global Advantage is to position and market greater Tucson as a 21st century international business center in order to advance long term sustainable economic growth for the Tucson region. The mission of the Global Advantage is to serve as a catalyst and a resource for the Tucson region to be recognized on a global business basis through providing research and development activities, marketing, branding, business and market development as well as international protocols. ATTACHMENTS: 1. A copy of the presentation that will be made by Mr. Wright will be provided as soon as it is available. JEFFREY H. WEIR, CEcD ECONOMIC DEVE a PM ENT ADM. CHUCK SWEET TOWN MANAGER jiiiii GlobaIADVANTAGE An international business development network Stimulating Economic Growth Through Strategic Alliances A Program of the University of Arizona Office of Economic Development What Is Global Advantage © Alliance Builder For Sustainable Economic Activity o Business Accelerator For SME's Through Research Parks and Universities ' Catalyst For Technology Development£t Commercialization Initiatives l GlobalADVANTAGE M nxnMoisl buYtRs W.dapmYu rgt..pk Scope of Work Vision: Position and market Tucson as a 21st century international business center G Mission: Operating within the University of Arizona Office of Economic Development,Global Advantage will be both a catalyst and a resource for the region to be a player on the global business stage through research and development activities,marketing, branding,business and market development as well as international protocols. C Action: Global Advantage facilitates and promotes region to region RaD and strategic economic alliances between greater Tucson and key business centers worldwide through universities and research parks. Long term benefits may include increased international trade and investment within a network �i� of interconnected regions. lit,GlobalADVANTAGE M nwnrlcnal Dusnfa tlewlopm�nnflwPk 1 Arizona's Export Based Economy $5,000,000.00 $4,500,000.00 ❑Mexico $4,000,000.00 ■Canada $3,500,000.00 _ II Malasyia $3,000,000.00 ❑Germany $2,500,000.00 United Kingdom $2,000,000.00 ■China $1,500,000.00 ' I ■France $1,000,000.00 r ■Israel $500,000.00 -1-1 -I i ❑Switzerland $0.00 Sin Thousands Aq 0 'A_7 ,Z ,Z '\' 1,Z V,Z .iP!GlobalADVANTAGE M n..ewan.l b....d.....n..l nn... Global Advantage Coordinating Activities I Cooperative Program Management for Incoming International High-Technology Business Delegations First responders group for international business interaction 'a International Protocol Development o Market Data Ft Intelligence 'o International Trade and Investment Development o Marketing and Branding o Region to Region Partnerships Ottawa,Canada Manchester UK Zurich,Switzerland Berlin,Germany Mexico(pending) Israel(pending) France(potential) China(???) J6GlobaIADVANTAGE M.n..ntmal buvess...tvn...,n.Nw./ Targeted Technology Sectors O Bioscience/Biotechnology D Information Technology r, 0 Environmental Technology 0 .7 ii� Communications 'L-------.),,-,..;. � / O Aerospace ='�. a_i.„' 0 Defense Systems ., V' 0 j Optics/Photonics 0 Plastics Et Advanced Materials O Nanotechnology AAGlobaIADVANTAGE M nl.n....n.buf.bt de...pm.,nnw.k 2 Expected Long-Term Outcomes 'e Location of companies in complimentary technologies in partner cities o University R a D partnerships Technology Development Commercialization New Company Creation (Research Park collaborations CO Technology partnerships Joint Ventures Co-Development 'fl Sales of products and services o Increased foreign investment (Increased foreign trade 'o Creation of a point of entry to UK and western Europe Creation of point of entry to western US markets and Mexico through Tucson GlobaIADVANTAGE M ntem+Ibnal buvRa U•wltprrrl natwrM Service Packages and Programs Qo University Partnerships 0 Faculty ft Student Exchanges Joint Ventures(Grants,joint research) ®Research Park Partnerships 0 Entrepreneurship V)Cluster Development C Marketing ft Branding • Cross-Market Regions • Web Based Promotions • Communications Strategy 0 Business Development • Companies will be given up to 4 weeks free business accommodation at UASTP to undertake business development initiatives in the host market • Assessment of visiting companies market opportunities through Global Advantage working group. • While in host market,visiting company can team with a local"mentor" to work with as needed • Video Conferencing for B2B meetings or cluster building exercises 0 Interaction with University of Arizona O Practical assistance to visiting companies GlobaIADVANTAGE M nlema4enal Duvtss CeMbpnMnl n•tvpk Global Advantage Partnering Organizations Office of the Mayor-City of Tucson Pima County Government Towns of Oro Valley and Marana University of Arizona Office of US Congressman Jim Kolbe United States Department of Commerce University of Arizona Office of the Associate Vice President for Economic Development University of Arizona Science and Technology Park Regional Economic Development Corporation Tucson Metropolitan Chamber of Commerce Metropolitan Tucson Convention ft Visitors Bureau Pima County Community College Arizona Department of Commerce Southern Arizona Tech Council ft High Tech Clusters National Law Center for Inter-American Free Trade Canadian Consul Office-Tucson Ottawa Center for Research and Innovation Manchester Investment Development Agency Service Manchester Science Park Adelsdorf Science City �aattO��pTechBB .ir GlobaIADVANTAGE M nt•maYonal buf•na 0e.doprrMt MIwPk 3 GlobaIADVANTAGE An international business development network .:. I 1.-`4e 71 �w E0111 A Program of the University of Arizona Office of Economic Development 4 3 TOWN OF ORO VALLEY STUDY SESSION COUNCIL COMMUNICATION MEETING DATE: FEBRUARY 23, 2005 TO: HONORABLE MAYOR& COUNCIL FROM: Chuck Sweet, Town Manager SUBJECT: DISCUSSION REGARDING SETTING THE TIME FOR TOWN COUNCIL STUDY SESSIONS TO BEGIN NO EARLIER THAN 5:30 P.M. SUMMARY: At the February 2, 2005 Town Council Meeting, Vice Mayor Gillaspie asked that an agenda item be added for discussion and consideration regarding Study Session meeting times. He has suggested that Study Sessions begin no earlier than 5:30 p.m. This items is being brought forward tonight for Council's discussion and direction. ATTACHMENT: 1. February 2, 2005 Minute Excerpt (Item 4) z_. / 2 IF .410(46.4 4 41 A Alerili A_f_i 11'-'-- ----------- own Manager IF 02/02/05 Minutes,Town Council Regular Session 7. The walls as specified in condition#6 must be constructed during Phase 1. 8. A minimum 5' 7' landscape buffer must be maintained A buffer no less than 5' must be provided between the north drainage wall and the existing trees on the south side of the Tearse's property. The north drainage wall if necessary must be established in a manner to preserve the existing vegetation. 9. There will be no permanent grill facilities within the snack bar area. 10.No loudspeakers or PA systems within the pool area. 11. The pool hours will be limited to Sam-bpm and beyond these hours only lap swimming can occur. 12. The proposed layout must be revised as follows: provide an additional parking space on either side of PV 12, PV 11, and PV 10 as landscaped areas, convert 3 spaces adjacent to PV2 to compact spaces and if possible, create another 3 feet of landscaped area adjacent to CF7 (the corresponding tree number is reflected on the Native Plant Preservation Plan). MOTION carried 6—0. 3. RESCHEDULING THE REGULAR MEETING FROM WEDNESDAY, FEBRUARY 16, 2005 TO TUESDAY, FEBRUARY 15, 2005 MOTION: A MOTION was made by Council Member Parish and SECONDED by Council Member Dankwerth to Table this item. MOTION carried 6—0. Therefore, the regular 2nd meeting of the month will be held on Wednesday, February 16, 2005. 4. FUTURE AGENDA ITEMS Vice Mayor Gillaspie asked that a future Agenda item be added to discuss the times of when Council Study Sessions should be held. CALL TO AUDIENCE—None. ADJOURNMENT MOTION: A MOTION was made by Council Member Dankwerth and SECONDED by Council Member Parish to ADJOURN the regular session at 7:55 p.m. MOTION carried 6-0. Respectfully submitted, Kathryn E. Cuvelier, CMC Town Clerk I hereby certify that the foregoing minutes are a true and correct copy of the minutes of the regular session of the Town of Oro Valley Council of Oro Valley, Arizona held on the 2nd day of February 2005. I further certify that the meeting was duly called and held and that a quorum was present.